Company Overview
Legend Biotech Corporation operates as a biopharmaceutical entity dedicated to discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications across the United States, China, and Europe. The company functions within the Healthcare sector and specifically the Biotechnology industry, where it focuses on advancing innovative treatments for complex disease states. Its financial scale is represented by a market capitalization of $3.31B, annual revenue of $1.03B, and an employee base of 2,900 individuals. These valuation and revenue figures indicate that the company holds a significant position within the biotechnology landscape, having achieved substantial revenue generation while maintaining a workforce capable of supporting its global research and development activities in oncology.
Financial Health
The company reported revenue of $1.03B over the trailing twelve months, with a net income of -$296.8M and EBITDA of -$127.1M. The substantial gap between the positive revenue of $1.03B and the negative net income of -$296.8M reveals a cost structure characterized by high operating expenses, which is typical for biotechnology firms in the development phase where research and development costs significantly outpace current sales. Free cash flow stands at -$133.9875M, indicating that the company is currently consuming cash to fund its operations and growth initiatives rather than generating surplus liquidity. This negative free cash flow suggests limited immediate financial flexibility for large-scale dividends or acquisitions without external capital raising or operational efficiency improvements. The gross margin is 20.0%, while the operating margin is -6.7% and the profit margin is -28.8%, indicating that while the cost of goods sold is controlled relative to revenue, overall operational and profit structures are currently loss-making due to the capital-intensive nature of cell therapy development. The company holds $948.60M in cash against $413.70M in debt, resulting in a debt-to-equity ratio of 41.28, which suggests a balance sheet that is leveraged but supported by a substantial cash reserve. The current ratio of 1.96 indicates that the company possesses strong short-term liquidity, with current assets nearly double its current liabilities, providing a buffer for meeting near-term obligations. Return on equity is -29.1% and return on assets is -5.0%, revealing that management effectiveness, measured by these return metrics, is currently negative as the company invests capital to build a pipeline that has not yet yielded profitability.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive net income, whereas the forward P/E is 15.54, implying that the market is pricing the stock based on expected future earnings growth rather than current profitability. The price-to-book ratio is 3.30, indicating that the market is valuing the company at a premium of 3.3 times its book value, reflecting investor confidence in the intangible assets and future potential of its cell therapy pipeline. The price-to-sales ratio is 3.21 and the EV/EBITDA is -47.80, suggesting that traditional earnings-based valuation metrics are less relevant here and that the market is focusing on revenue generation and sales multiples as primary valuation drivers. The 52-week high is $45.30 and the 52-week low is $16.24; without a specific current price provided in the facts, the valuation range indicates significant volatility within the past year, with the stock capable of trading anywhere within this $29.06 spread. The beta value is 0.06, which implies that the stock price is virtually uncorrelated with the broader market movements, exhibiting extremely low volatility relative to the overall market index.
Growth & Income
Revenue growth year-over-year is 64.2%, while earnings growth is N/A due to the company's net loss position. Since the company is not currently profitable, earnings cannot grow faster than revenue in the traditional sense, and the focus remains on expanding the revenue base to eventually support profitability. As a non-dividend payer, the company pays no dividends with a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available capital back into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms seeking to scale their product portfolios before generating sustainable cash flows. The overall growth and income profile is defined by rapid revenue expansion of 64.2% paired with a complete absence of dividend income, positioning the asset as a pure growth play dependent on future clinical successes and commercial adoption.